Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics reported a second quarter net loss of $36.2 million and ended the period with $1.1 billion in cash, providing a runway expected to extend into the second half of 2029. The company announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial, showing statistically significant reductions in the Robart’s Histopathology Index score of 9.2 and 10.7 points, respectively.
Key figures
- Eps
- -0.36
- Net loss
- 36200000
- Cash runway
- Second half of 2029
- Ga expenses
- 16100000
- Rd expenses
- 65500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.